This company listing is no longer active
Bionomics Past Earnings Performance
Past criteria checks 0/6
Bionomics's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been declining at an average rate of 42.6% per year.
Key information
-3.4%
Earnings growth rate
27.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -42.6% |
| Return on equity | -52.2% |
| Net Margin | -413.9% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bionomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 6 | -25 | 7 | 0 |
| 30 Sep 22 | 6 | -23 | 7 | 0 |
| 30 Jun 22 | 6 | -22 | 8 | 0 |
| 31 Mar 22 | 3 | -22 | 8 | 0 |
| 31 Dec 21 | 0 | -22 | 8 | 0 |
| 30 Sep 21 | 1 | -15 | 7 | 0 |
| 30 Jun 21 | 1 | -9 | 6 | 0 |
| 31 Mar 21 | 1 | -4 | 5 | 0 |
| 31 Dec 20 | 2 | 1 | 5 | 0 |
| 30 Sep 20 | 2 | -3 | 5 | 0 |
| 30 Jun 20 | 3 | -6 | 5 | 0 |
| 31 Dec 19 | 6 | -5 | 5 | 0 |
| 30 Sep 19 | 7 | -8 | 6 | 0 |
| 30 Jun 19 | 7 | -10 | 8 | 0 |
| 31 Mar 19 | 8 | -20 | 11 | 0 |
| 31 Dec 18 | 8 | -28 | 11 | 0 |
| 30 Sep 18 | 10 | -27 | 11 | 0 |
| 30 Jun 18 | 12 | -25 | 11 | 0 |
| 31 Mar 18 | 19 | -15 | 9 | 0 |
| 31 Dec 17 | 27 | -6 | 8 | 0 |
| 30 Sep 17 | 27 | -6 | 8 | 0 |
| 30 Jun 17 | 27 | -7 | 8 | 0 |
| 31 Mar 17 | 22 | -12 | 10 | 0 |
| 31 Dec 16 | 16 | -17 | 12 | 0 |
| 30 Sep 16 | 18 | -17 | 11 | 0 |
| 30 Jun 16 | 19 | -17 | 11 | 0 |
| 31 Mar 16 | 19 | -19 | 10 | 0 |
| 31 Dec 15 | 18 | -21 | 9 | 0 |
| 30 Sep 15 | 17 | -19 | 9 | 0 |
| 30 Jun 15 | 15 | -17 | 9 | 0 |
| 31 Mar 15 | 22 | -6 | 7 | 0 |
| 31 Dec 14 | 29 | 4 | 5 | 0 |
| 30 Sep 14 | 28 | 4 | 5 | 0 |
| 30 Jun 14 | 27 | 3 | 5 | 0 |
| 31 Mar 14 | 19 | -5 | 5 | 0 |
| 31 Dec 13 | 12 | -13 | 5 | 0 |
| 30 Sep 13 | 12 | -11 | 5 | 0 |
| 30 Jun 13 | 12 | -10 | 5 | 0 |
| 31 Mar 13 | 13 | -7 | 5 | 0 |
| 31 Dec 12 | 13 | -4 | 4 | 0 |
| 30 Sep 12 | 12 | -3 | 4 | 0 |
Quality Earnings: B1N is currently unprofitable.
Growing Profit Margin: B1N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B1N is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare B1N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B1N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: B1N has a negative Return on Equity (-52.21%), as it is currently unprofitable.